Bavituximab, a chimeric monoclonal antibody (MW = 145.3 kDa) binding to the beta-2 glycoprotein I domain of PS, has been radiolabelled with the β + emitter arsenicum-74 (74As, T1/2 = 17.8 days) for tumour vasculature PET imaging, and with the β-,γ emitter 77As (T1/2 = 38.8 h) for SPECT imaging and potential tumour vasculature endothelium therapy [42-44]. The gene discussed is APOH; the disease is neoplasm.